Tag

mots-c

The Foundation

Why Some Peptides Need to Be Cycled — And Why Others Don’t

July 8, 2026

A science-led guide to receptor biology: why continuous signaling can stop working, why your body is built to listen in pulses, and why the answer is different for every compound.

Here’s a question worth asking honestly, because the real answer is more interesting than a blanket rule in either direction: do peptides need to be cycled, or can you just stay on them indefinitely?

The honest answer is that it depends entirely on how a given peptide actually signals to your cells. Some genuinely do need breaks, for reasons rooted in real, well-documented receptor biology. Others don’t work through a mechanism that requires cycling at all. Treating every peptide the same way — always cycle, or never cycle — misses the actual, more useful question.

Your cells can stop listening

Many peptides work by binding to a class of cell-surface receptor called a G-protein coupled receptor, or GPCR — one of the most common signaling mechanisms in the entire body. Here’s the part that explains everything else: when a GPCR is exposed to continuous, uninterrupted stimulation, the cell has a built-in response to that constant signal. It gets phosphorylated, binds a protein called β-arrestin, and is pulled inside the cell — physically removed from the surface where it could otherwise keep listening.1 This is called desensitization, and if the stimulation continues long enough, the cell goes further and actually reduces the total number of receptors it keeps on its surface at all — a deeper, longer-lasting change called downregulation.2

This isn’t a peptide-specific quirk. It’s a fundamental property of how this whole class of receptor is built, and it shows up throughout pharmacology under the name tachyphylaxis — a rapid drop in response to a drug or signal after repeated or continuous exposure.

The clearest example in all of endocrinology

There’s a real, well-documented illustration of this that makes the whole concept click: consider two people with the same underlying hormone deficiency, both needing replacement of a signaling hormone called GnRH. One receives it through a pump that delivers it in pulses, mimicking how the body naturally releases it roughly every 90 minutes. He undergoes normal puberty — his pituitary cells receive the message, respond, and get a rest before the next pulse. The other receives the exact same total amount of hormone, but delivered as a constant, continuous infusion instead of pulses. He fails to enter puberty at all. His pituitary cells, faced with an uninterrupted signal, simply downregulate their receptors and stop responding.3

The information was never just in the hormone existing. It was in the pattern — pulsed versus constant. This is such a reliable phenomenon that it’s used deliberately in medicine: continuous GnRH agonist therapy is a real clinical strategy for hormone-sensitive prostate cancer, precisely because it desensitizes the pituitary on purpose and shuts down testosterone production.

Where this actually applies to peptides

Growth hormone secretagogues — compounds like CJC-1295, Ipamorelin, and the GHRP-class peptides — work through exactly this kind of GPCR mechanism, binding receptors in the pituitary to stimulate a pulse of growth hormone release.4 Because they rely on the same receptor biology as the GnRH example above, continuous, uninterrupted stimulation genuinely risks the same outcome: a pituitary that becomes measurably less responsive over time, requiring a rest period for that responsiveness to reset.

This is the real, mechanistic case for cycling — not tradition, not a vague sense that “breaks are healthy,” but a specific, well-characterized cellular response to constant receptor stimulation.

Where it doesn’t apply the same way

Here’s the honest complication, and it’s the part a blanket rule always misses: not every peptide signals through this kind of receptor at all.

BPC-157, for example, doesn’t have an identified classical receptor the way GHRH or GHRP-class compounds do — its mechanism of action is still an open area of research, without the same well-mapped GPCR desensitization pathway.5 GHK-Cu works partly through effects on gene expression rather than the same receptor-binding-and-internalization cycle. Neither of these fits neatly into the same “continuous stimulation causes desensitization” framework that makes cycling mechanistically necessary for GH secretagogues.

That doesn’t mean every non-receptor peptide should automatically be used indefinitely without question — it means the reasoning has to be specific to the compound’s actual mechanism, not borrowed wholesale from a different class of peptide that happens to share the same category label.

What the research shows

What We KnowGPCR desensitization and downregulation are real, well-documented cellular responses to continuous receptor stimulation. The pulsatile-versus-continuous GnRH example is one of the most reliably replicated findings in endocrinology. GH secretagogues (CJC-1295, Ipamorelin, GHRP-class peptides) signal through this same receptor mechanism.
What We Don’t KnowThe precise timeline for desensitization and recovery varies by compound and by individual, and isn’t established with the same precision for every peptide in this class. For peptides without a classical identified receptor, such as BPC-157, whether or how a cycling framework applies at all is genuinely unresolved rather than simply “no.”
What That Means“Should I cycle this” isn’t a question with one universal answer. It’s a question about a specific compound’s specific mechanism. Peptides that signal through desensitizing GPCRs have a real, biological reason to include breaks. Peptides that work through different mechanisms need their own reasoning, not a rule borrowed from a different category.

Which axes actually need cycling

Here’s the same principle applied concretely — sorted by the actual receptor mechanism involved, not by category label. This is general mechanism-level information, not a dosing protocol; how any of this applies to a specific person is a question for a qualified healthcare provider.

Axis / MechanismExamplesWhy
GH axis (GHRH/GHRP receptors)CJC-1295, Tesamorelin, Ipamorelin, GHRP-2/6Classical GPCRs. Continuous stimulation drives the same desensitization/downregulation mechanism as the GnRH example above.
HPG axis (GnRH/kisspeptin receptors)Kisspeptin, GnRH agonistsThe textbook example of pattern-dependent signaling — pulsatile activation supports the axis, continuous exposure downregulates it deliberately (as in GnRH agonist therapy).
Melanocortin receptorsKPV, melanotan-class peptidesDocumented to desensitize with continuous exposure, similar in principle to other GPCR-mediated systems.
Mitochondrial / AMPK signalingMOTS-cActs intracellularly on AMPK rather than through a surface receptor that internalizes — doesn’t fit the same desensitization framework. Cycling logic here is not well established.
No identified classical receptorBPC-157Mechanism of action is still being mapped. Without a known receptor being desensitized, the GPCR-based case for cycling doesn’t apply — whether some other reason to cycle exists is a separate, open question.
Structural / non-receptor bindingTB-500, GHK-CuTB-500 works by binding actin directly, not a cell-surface receptor. GHK-Cu acts partly through gene expression and metal-ion chemistry. Neither fits the receptor-internalization mechanism this piece is about.

What this means for you

The useful question was never “do peptides need breaks, yes or no.” It’s “how does this specific compound talk to your cells, and what does that mechanism actually predict.”

A receptor that gets desensitized by constant stimulation has a real, mechanistic reason to rest. A compound that doesn’t work that way isn’t automatically safe to run forever without question — it just needs its own answer, grounded in its own biology, rather than an answer copied from somewhere else.

Sources

1. GPCR Desensitization: Acute and Prolonged Phases. PMC.

2. Desensitization and Tachyphylaxis in Pharmacology. JoVE Science Education; Receptor Regulation, Principles of Pharmacology.

3. Divergent expression patterns of pituitary gonadotropin subunit and GnRH receptor genes to continuous GnRH in vitro and in vivo. PMC. Pulsatile vs. continuous GnRH and pituitary receptor downregulation.

4. Growth hormone secretagogue receptor mechanism — GPCR-mediated pulsatile GH release.

5. BPC-157 mechanism of action — no identified classical receptor; ongoing research area.

This article is for research and educational purposes only. Nothing here is medical advice, and nothing here should be read as a recommendation regarding peptide use or dosing. Always consult a qualified healthcare provider.

Continue reading
Alcohol

The Science of Alcohol and the Female Body: What the Research Actually Shows

July 7, 2026

A science-led guide to what alcohol actually does to a woman’s brain, hormones, and sleep after 40 — and what the research shows about recovery.

You didn’t imagine it. Your relationship with alcohol changed somewhere after 40 — and so did what it’s actually doing to you.

The glass of wine that used to just feel relaxing now leaves you wide awake at 3am. The two drinks at dinner that never used to register now show up on your face the next morning. You haven’t gotten weaker. You haven’t lost your tolerance for fun. Your biology changed, and nobody sent you the memo.

Here’s the other thing that didn’t get a memo: how deeply woven alcohol is into the way women your age connect with each other. The girls’ night. The bottle split over two hours of real conversation. The nightcap that marks the end of a hard day. That ritual is real, and it matters, and this isn’t about taking it away from you or making you feel foolish for loving it. It’s about understanding, honestly, what it’s actually doing while it’s doing all that other good work too — so you get to decide with real information, not marketing.

Because that’s the thing nobody tells you: almost everything you’ve heard about alcohol being fine in moderation, or even good for you, came from somewhere with a reason to tell you that. “One glass for your heart” is advertising, dressed up as science. What follows is not that. It’s what the actual research shows, in your body, right now, at your age.

What alcohol actually does to your brain

Start with the part most women have never been told plainly: even light-to-moderate drinking is measurably associated with less brain volume.

A large 2022 study using brain imaging data from more than 36,000 UK Biobank participants found that alcohol intake was negatively associated with both gray matter volume — the neurons themselves — and white matter microstructure, the connective wiring between them.1 Critically, this wasn’t only showing up in heavy drinkers. The associations were apparent in people consuming an average of just one to two alcohol units per day — what most people would call completely normal, moderate drinking.

That said, the picture isn’t perfectly uniform across every study. Some research has found no measurable difference in brain structure at very light intake — under roughly seven units a week — with clearer volume loss showing up more consistently at 14 or more units weekly.2 So the honest read is: the risk is real and it scales with how much you drink, but it isn’t a hard cliff-edge where one glass of wine a week is equivalent to fourteen. More is worse, consistently, and the floor where “zero measurable effect” begins is still being worked out.

What’s actually happening mechanistically: alcohol is both water-soluble and fat-soluble, which means it passes directly into brain cells rather than needing to bind a receptor first.3 Once there, it enhances GABA signaling — your brain’s primary inhibitory system — which is why the first drink or two produces that loosening, relaxed feeling. It also suppresses glutamate, your brain’s main excitatory signal. When alcohol clears, that suppressed glutamate system rebounds, which is part of why a night of drinking can leave you feeling wired, anxious, or unable to sleep well the following night, even after just one or two drinks.

The hormone connection

This is the part that matters most for where you are right now, and it’s the part almost nobody explains clearly.

Alcohol increases the activity of an enzyme called aromatase, which converts testosterone into estrogen. This happens in multiple tissues throughout the body — not just one organ — including the ovaries, the liver, and fat tissue.4 For a woman already navigating the hormonal volatility of perimenopause or post-menopause, adding a substance that actively pushes your testosterone-to-estrogen ratio in one direction is not a neutral act. It’s adding noise to a system that’s already recalibrating on its own.

And this connects directly to something with real weight: alcohol consumption is one of the most well-established modifiable risk factors for breast cancer. Meta-analyses consistently show that breast cancer risk rises by roughly 7 to 10 percent for each daily drink, with women having two to three drinks per day showing about a 20 percent higher risk compared to non-drinkers.5 This relationship holds for both pre- and post-menopausal breast cancer, and it isn’t limited to heavy drinking — measurable increases in risk have been found even at less than one drink per day.6

The mechanism lines up with what we just covered: alcohol’s metabolite, acetaldehyde, causes direct DNA damage, and the aromatization-driven rise in estrogen adds hormonal fuel to estrogen-sensitive tissue.7 This is not a reason for alarm or a reason to feel guilty about your Friday glass of wine. It’s information you deserve to have, stated plainly, so that whatever you decide, you’re deciding with the full picture instead of the marketing one.

Sleep, disrupted from the inside

You may already suspect this one, because you’ve lived it: the sleep you get after a drink is not the same sleep you get without one.

Alcohol disrupts the architecture of sleep — specifically slow-wave sleep and REM sleep, the two stages most responsible for feeling genuinely rested and cognitively sharp the next day.8 Even a single drink shifts you toward a lighter, more fragmented kind of sleep, with more frequent waking that you may not even consciously register. This is separate from hangover — this is just what one glass of wine does to your night’s sleep, full stop.

For a woman already dealing with the sleep disruption that often comes with perimenopause and menopause, alcohol is compounding a problem you’re already fighting, not helping you relax your way out of it.

The mitochondrial cost

There’s one more piece of this, and it’s the part that explains why the exhaustion after drinking runs deeper than just poor sleep.

When your body processes alcohol, it doesn’t just metabolize a substance — it spends a resource to do it. Ethanol is converted first into acetaldehyde, a genuinely toxic compound, and then into acetate, which your body can use as fuel.9 That conversion runs on a molecule called NAD+, which every cell in your body depends on to produce cellular energy. Processing alcohol consumes NAD+ at a real rate, shifting the balance of NAD+ to its reduced form, NADH, and that shift is the rate-limiting step in how quickly your body can clear alcohol at all.9 While your liver is busy spending NAD+ on alcohol clearance, that’s NAD+ your mitochondria — your cells’ energy-producing machinery — aren’t getting for their own work.

This is a genuinely under-told part of the story. The 3pm crash the day after drinking, the sense that your energy just isn’t there even after a full night’s sleep — some of that is the direct downstream cost of a metabolic system that spent the night doing overtime on cleanup instead of its usual maintenance.

This is also why mitochondrial energy metabolism is an active area of research interest for anyone thinking seriously about recovery and resilience after 40 — not specific to alcohol, but relevant to it. One compound of particular research interest here is MOTS-c, a peptide encoded directly in mitochondrial DNA that’s been studied for its role in activating AMPK, the master regulator of cellular energy balance.10 We’re not suggesting MOTS-c as a fix for a hangover or a way to drink without consequence — that’s not what the research supports, and that’s not how any of this works. But if you’re curious about the compound and what the actual research shows about mitochondrial energy pathways, that’s a natural next place to look.

See MOTS-c in The Peptides for what the research actually shows.

What the research shows

What We KnowAlcohol is associated with measurable brain volume loss even at low-to-moderate intake, with the association strengthening as intake increases. It measurably increases aromatization of testosterone to estrogen across multiple tissues. It is one of the most well-established modifiable risk factors for breast cancer, with risk rising roughly 7–10% per daily drink. It disrupts slow-wave and REM sleep even at low doses.
What We Don’t KnowThe exact threshold, if one exists, below which alcohol has no measurable effect on brain structure is not settled — some studies find no difference under roughly 7 units weekly, others find effects at lower levels. Whether moderate drinkers’ brain changes are reversible with abstinence, the way some changes in heavier drinkers appear to be, has not been established by long-term study. Individual variation in enzyme activity (alcohol dehydrogenase, aromatase) means these population-level statistics don’t predict any one woman’s personal risk precisely.
What That MeansThis isn’t a case for panic over an occasional glass of wine, and it isn’t a case for the “it’s basically harmless” story either. The honest middle is that alcohol is a genuine, dose-dependent cost to your brain, your hormones, and your sleep — a cost that compounds with the hormonal transition many of you are already navigating. What you do with that information is yours to decide. But it should be an informed decision, not one made on the strength of “one glass is good for your heart.”

What this means for you, after 40

Here’s what I actually want you to walk away with. This was never about telling you to feel guilty over wine with your best friend, or about pretending that ritual doesn’t matter. It matters. Connection matters. An evening that leaves you feeling seen and unwound has real value — value that doesn’t show up in a bloodwork panel but is worth something all the same.

What this is about is making sure you’re the one deciding, with the actual research in hand, rather than a decades-old marketing story about hearts and merlot doing the deciding for you. You get to weigh the ritual against the biology, honestly, for yourself. You don’t get to do that if half the information has been dressed up as harmless.

If you’re navigating perimenopause or post-menopause and trying to understand why your tolerance, your sleep, or your mood around alcohol has shifted, that’s not you losing your grip — that’s your hormonal environment changing, and alcohol interacting with that new environment differently than it used to. You’re allowed to notice that, respect it, and make a different choice than you did at 30, without it meaning anything was wrong with how you drank before.

And if what you’re really asking is “okay, so what do I actually do with this” — that’s the right next question, and it’s one worth having a real answer to, not just an awareness of the problem.

That’s exactly what the Recovery & Repair After Drinking guide is for — it ties together the three systems this piece just walked through — sleep, gut, and mitochondrial energy support — into one practical resource, rather than leaving you with three separate problems and no throughline between them.

For more on the hormonal shifts underlying this transition, see the Hormonal Health pillar. For the specific question of whether red wine has real heart benefits, see our upcoming Claim Check on the French Paradox.

Sources

1. Daviet, R., et al. (2022). Associations between alcohol consumption and gray and white matter volumes in the UK Biobank. Nature Communications.
2. Topiwala, A., et al. Alcohol consumption and MRI markers of brain structure and function: Cohort study of 25,378 UK Biobank participants. NeuroImage: Clinical.
3. Basic pharmacology of ethanol absorption and distribution — standard reference physiology.
4. Purohit, V. (2000). Can alcohol promote aromatization of androgens to estrogens? A review. Alcohol.
5. Hamajima, N., et al. (2002). Alcohol, tobacco and breast cancer — collaborative reanalysis of individual data from 53 epidemiological studies. British Journal of Cancer.
6. Systematic review and meta-analysis of prospective cohort studies, alcohol and female breast cancer risk (2024). PMC.
7. American Cancer Society / Surgeon General’s Advisory on Alcohol and Cancer Risk (2025).
8. Walker, M. — sleep architecture and alcohol, as referenced in peer-reviewed sleep literature.
9. Ethanol metabolism, NAD+/NADH ratio, and the rate-limiting role of alcohol/aldehyde dehydrogenase — standard biochemistry reference.
10. MOTS-c and AMPK activation in mitochondrial energy metabolism — see The Peptides: MOTS-c for full citation detail.

This article is for research and educational purposes only. Nothing here is medical advice, and nothing here should be read as a recommendation regarding alcohol use. Always consult a qualified healthcare provider regarding your own health.

Continue reading
The Peptides

MOTS-c

June 29, 2026
Cell Rituals · The Peptides
MOTS-c
Mitochondrial-Derived Peptide — What the Research Actually Shows
Mitochondrial-Derived · 16 aa CAS 1627580-64-6 AMPK · Retrograde Signaling Metabolic Health · Insulin Sensitivity · Longevity · Exercise Mimetic
01 · What It Is

The only peptide in this catalog encoded not in your nuclear DNA — but in your mitochondria.

MOTS-c — Mitochondrial Open Reading Frame of the 12S rRNA-c — is a 16-amino acid peptide with an origin story unlike anything else in this catalog. It is not encoded in nuclear DNA. It is encoded in the mitochondrial genome — specifically in the 12S rRNA region (MT-RNR1 gene) — a stretch of mitochondrial DNA previously thought to be non-coding. Its discovery in 2015 by Lee et al. at the USC Davis School of Gerontology established for the first time that mitochondria have their own peptide-based signaling system, capable of communicating directly with the nucleus to regulate gene expression.1

This origin is not a detail. It fundamentally changes what MOTS-c is. Every other peptide in this section is encoded in nuclear DNA and acts on cells from the outside in. MOTS-c is generated from within the mitochondria themselves — the cellular organelles that produce energy, regulate metabolism, and decline in number and efficiency with age. MOTS-c is the mitochondria’s own signal that something needs to change.

MOTS-c circulates in human plasma and declines with age — consistent with the broader pattern of mitochondrial decline in aging tissue. Its sequence (MRWQEMGYIFYPRKLR) is highly conserved across 14 species, with the first 11 residues identical from mice to humans — a degree of conservation that indicates this peptide is performing a function evolution has prioritized across hundreds of millions of years.2

It has also attracted the attention of the World Anti-Doping Agency (WADA), which added MOTS-c to its monitoring program — a marker of how seriously the exercise physiology and performance research community takes its documented metabolic effects.

CAS Number
1627580-64-6
Molecular Weight
2,174.6 g/mol
Molecular Formula
C₁₀₁H₁₅₂N₂₈O₂₂S₂
Peptide Class
Mitochondrial-derived · 16 aa
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Mechanism
AMPK activation · Retrograde signaling
Origin
Endogenous · Mitochondrial DNA
02 · How It Works

Retrograde signaling — when mitochondria send a message to the nucleus, the whole cell listens.

Under normal resting conditions, MOTS-c stays in the mitochondria. When cells experience metabolic stress — elevated glucose, insulin resistance, oxidative load, caloric excess, or the cumulative stress of aging — mitochondria upregulate MOTS-c production and release it into the cytoplasm. It then translocates to the nucleus. This is called retrograde signaling: communication from organelle to nucleus, the cell’s internal reporting system.

Once in the nucleus, MOTS-c activates AMPK — AMP-activated protein kinase, the master sensor of cellular energy status. AMPK activation triggers a coordinated metabolic reset: increased glucose uptake, enhanced fatty acid oxidation, stimulation of mitochondrial biogenesis, and suppression of energy-wasting pathways. It is, in effect, the signal that tells the cell to run more efficiently.

Glucose uptake independent of insulin

One of MOTS-c’s most documented and clinically significant effects is its ability to enhance glucose uptake in skeletal muscle independently of insulin signaling. It does this by promoting GLUT4 transporter translocation to the cell surface — the same mechanism insulin uses — but through a parallel AMPK-dependent pathway that does not require insulin receptor activation.3 This has direct relevance to insulin resistance: when the insulin receptor pathway is impaired, MOTS-c’s AMPK pathway provides an alternative route for glucose clearance from the bloodstream.

Mitochondrial biogenesis via PGC-1α

AMPK activation by MOTS-c upregulates PGC-1α — the master regulator of mitochondrial biogenesis. PGC-1α drives the creation of new mitochondria and the optimization of existing ones, increasing cellular energy capacity and reducing the proportion of dysfunctional mitochondria that generate reactive oxygen species rather than ATP. This is the mechanism by which MOTS-c functions as what the research literature calls an exercise mimetic — it activates many of the same adaptive pathways that sustained physical exercise activates, including increased mitochondrial density and improved metabolic flexibility.4

The folate cycle connection

Lee et al.’s founding 2015 paper also identified a more granular mechanism: MOTS-c inhibits the folate cycle and de novo purine biosynthesis in skeletal muscle under metabolic stress — redirecting metabolic resources toward energy production rather than biosynthesis. This metabolic rebalancing prevents the accumulation of intermediates that impair insulin signaling and contributes to the AMPK-dependent glucose clearance effect.1 It is a level of mechanistic specificity unusual in the peptide research literature and one reason the 2015 paper attracted significant scientific attention.

03 · What the Research Shows

The evidence, read honestly.

MOTS-c has accumulated a substantial research base since its 2015 discovery — published across multiple independent research groups in journals including Cell Metabolism, Diabetes, and Frontiers in Endocrinology. The evidence base is more independently diverse than most peptides in this catalog. The consistent caveat: no large-scale human RCT has been completed. Most data is from rodent models and cell culture.

Metabolic Regulation & Insulin Sensitivity
What We Know The founding 2015 Lee et al. Cell Metabolism paper demonstrated that MOTS-c administration in high-fat diet mice prevented diet-induced obesity and insulin resistance, with treated mice eating the same diet as controls but maintaining metabolic health — one of the most striking findings in the MOTS-c literature.1 The mechanism — AMPK-dependent GLUT4 translocation enhancing glucose uptake independent of insulin — was confirmed in muscle cell models by Reynolds et al. (2021).3 MOTS-c also raises intracellular NAD⁺ levels, countering the NAD⁺ decline associated with aging and metabolic dysfunction, and inhibits the folate cycle to redirect resources toward energy production. In a separate study, MOTS-c countered the metabolic effects of menopause in an ovariectomized mouse model in an AMPK-dependent manner — a finding with direct relevance to perimenopausal and postmenopausal women.5
What We Don’t Know No large-scale human RCT on insulin sensitivity or metabolic outcomes has been completed. The mouse obesity prevention finding is striking but has not been replicated in a controlled human trial. Optimal dosing, timing, and administration route for metabolic effects in humans are not established. Whether exogenous MOTS-c produces equivalent metabolic effects to endogenous MOTS-c signaling — given that the endogenous compound is released in response to specific cellular stress conditions — is an open question.
What That Means The metabolic evidence base is the strongest in the MOTS-c literature, with the most mechanistic depth and the most independently replicated findings. The menopause-specific data is the most directly relevant finding for the Cell Rituals audience — AMPK-dependent reversal of menopausal metabolic dysfunction is documented in animal models. The honest framing: compelling mechanism, compelling animal data, and human trial evidence that is early rather than established.
Exercise Mimetic & Physical Performance
What We Know MOTS-c levels rise in human blood during exercise — a finding documented in human subjects, not just animal models.6 This establishes MOTS-c as part of the body’s genuine exercise response, not merely a compound that mimics exercise pharmacologically. In aged mice, MOTS-c administration improved running endurance by approximately 20% while simultaneously improving glucose tolerance and insulin sensitivity parameters.7 The World Anti-Doping Agency (WADA) added MOTS-c to its monitoring program — a marker that the exercise physiology and performance research community regards its ergogenic potential as real enough to track. MOTS-c activates skeletal muscle stress response pathways and promotes cellular adaptations similar to sustained exercise training at the molecular level.
What We Don’t Know The endurance improvement data is from aged mice. Whether equivalent performance enhancement occurs in humans — and at what dose — has not been established in controlled trials. Whether the WADA monitoring designation reflects documented human performance enhancement or precautionary monitoring of a compound with that potential is an important distinction. The relationship between exogenous MOTS-c and the body’s own exercise-induced MOTS-c signaling is not fully characterized.
What That Means The exercise mimetic designation is scientifically grounded — MOTS-c is genuinely part of the human exercise response and activates overlapping molecular pathways. The performance data in aged animals is meaningful for the aging research context. The honest framing for humans: MOTS-c activates exercise-adaptive pathways; whether it produces meaningful physical performance benefits in humans has not been established by controlled trials.
Anti-Aging & Longevity
What We Know MOTS-c plasma levels decline with age in humans — establishing it as part of the biological aging signature, not just an incidentally measured compound.2 In animal models, MOTS-c extended lifespan in C. elegans and reduced age-related oxidative stress and mitochondrial dysfunction in skeletal muscle of aged mice.8 It upregulates antioxidant pathways including Nrf2, reduces inflammatory cytokine production via NF-κB suppression, and attenuates the accumulation of oxidative damage to mitochondrial DNA — three mechanisms directly implicated in biological aging. Its mitochondrial biogenesis effects via PGC-1α address one of the most well-established hallmarks of aging: declining mitochondrial number and function.
What We Don’t Know No human longevity data exists. The C. elegans lifespan extension is from a model organism with limited translational relevance to human aging. Whether MOTS-c’s mitochondrial effects translate to measurable lifespan or healthspan extension in humans is unknown. The relationship between declining endogenous MOTS-c levels and biological aging — whether the decline is a cause of accelerated aging or a consequence of it — has not been established.
What That Means The anti-aging findings are mechanistically coherent — MOTS-c addresses multiple established hallmarks of aging simultaneously through a single upstream mechanism. The age-dependent plasma decline establishes it as part of the biology of aging, not a peripheral finding. The evidence base is preliminary for longevity specifically; it is stronger for the metabolic and mitochondrial health effects that constitute what most people mean by healthy aging.
Neuroprotection & Cognitive Function
What We Know MOTS-c crosses the blood-brain barrier in animal models and has been detected in cerebrospinal fluid. Cohen et al. (2022) demonstrated that MOTS-c reduced amyloid-beta accumulation in Alzheimer’s disease models.9 Lu et al. (2023) showed improved hippocampal-dependent memory in aged mice following MOTS-c treatment.10 The mechanisms proposed include reduction of neuroinflammation via microglial suppression, mitochondrial protection in neurons (which are particularly dependent on mitochondrial function), and AMPK-mediated improvement in brain energy metabolism. Given that neurons are among the most metabolically demanding cells in the body, MOTS-c’s metabolic efficiency effects have particular relevance to brain function.
What We Don’t Know All neurological data is from animal models. No human cognitive or neuroprotective trials exist. The Alzheimer’s model findings are from genetically engineered mice — not a direct model of sporadic human Alzheimer’s disease. Whether MOTS-c crosses the blood-brain barrier in meaningful quantities in humans after peripheral administration has not been established.
What That Means The neuroprotective findings are early-stage and mechanistically plausible — the brain’s energy dependence on mitochondrial function makes MOTS-c a logical candidate for neuroprotective research. The amyloid-beta and memory findings are intriguing. They are animal model data, not clinical evidence. This is an area to watch as research develops, not a clinical conclusion.
Cell Rituals · The Peptides
MOTS-c
Mitochondrial-Derived Peptide — What the Research Actually Shows
Mitochondrial-Derived · 16 aa CAS 1627580-64-6 AMPK · Retrograde Signaling Metabolic Health · Insulin Sensitivity · Longevity · Exercise Mimetic
01 · What It Is

The only peptide in this catalog encoded not in your nuclear DNA — but in your mitochondria.

MOTS-c — Mitochondrial Open Reading Frame of the 12S rRNA-c — is a 16-amino acid peptide with an origin story unlike anything else in this catalog. It is not encoded in nuclear DNA. It is encoded in the mitochondrial genome — specifically in the 12S rRNA region (MT-RNR1 gene) — a stretch of mitochondrial DNA previously thought to be non-coding. Its discovery in 2015 by Lee et al. at the USC Davis School of Gerontology established for the first time that mitochondria have their own peptide-based signaling system, capable of communicating directly with the nucleus to regulate gene expression.1

This origin is not a detail. It fundamentally changes what MOTS-c is. Every other peptide in this section is encoded in nuclear DNA and acts on cells from the outside in. MOTS-c is generated from within the mitochondria themselves — the cellular organelles that produce energy, regulate metabolism, and decline in number and efficiency with age. MOTS-c is the mitochondria’s own signal that something needs to change.

MOTS-c circulates in human plasma and declines with age — consistent with the broader pattern of mitochondrial decline in aging tissue. Its sequence (MRWQEMGYIFYPRKLR) is highly conserved across 14 species, with the first 11 residues identical from mice to humans — a degree of conservation that indicates this peptide is performing a function evolution has prioritized across hundreds of millions of years.2

It has also attracted the attention of the World Anti-Doping Agency (WADA), which added MOTS-c to its monitoring program — a marker of how seriously the exercise physiology and performance research community takes its documented metabolic effects.

CAS Number
1627580-64-6
Molecular Weight
2,174.6 g/mol
Molecular Formula
C₁₀₁H₁₅₂N₂₈O₂₂S₂
Peptide Class
Mitochondrial-derived · 16 aa
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Mechanism
AMPK activation · Retrograde signaling
Origin
Endogenous · Mitochondrial DNA
02 · How It Works

Retrograde signaling — when mitochondria send a message to the nucleus, the whole cell listens.

Under normal resting conditions, MOTS-c stays in the mitochondria. When cells experience metabolic stress — elevated glucose, insulin resistance, oxidative load, caloric excess, or the cumulative stress of aging — mitochondria upregulate MOTS-c production and release it into the cytoplasm. It then translocates to the nucleus. This is called retrograde signaling: communication from organelle to nucleus, the cell’s internal reporting system.

Once in the nucleus, MOTS-c activates AMPK — AMP-activated protein kinase, the master sensor of cellular energy status. AMPK activation triggers a coordinated metabolic reset: increased glucose uptake, enhanced fatty acid oxidation, stimulation of mitochondrial biogenesis, and suppression of energy-wasting pathways. It is, in effect, the signal that tells the cell to run more efficiently.

Glucose uptake independent of insulin

One of MOTS-c’s most documented and clinically significant effects is its ability to enhance glucose uptake in skeletal muscle independently of insulin signaling. It does this by promoting GLUT4 transporter translocation to the cell surface — the same mechanism insulin uses — but through a parallel AMPK-dependent pathway that does not require insulin receptor activation.3 This has direct relevance to insulin resistance: when the insulin receptor pathway is impaired, MOTS-c’s AMPK pathway provides an alternative route for glucose clearance from the bloodstream.

Mitochondrial biogenesis via PGC-1α

AMPK activation by MOTS-c upregulates PGC-1α — the master regulator of mitochondrial biogenesis. PGC-1α drives the creation of new mitochondria and the optimization of existing ones, increasing cellular energy capacity and reducing the proportion of dysfunctional mitochondria that generate reactive oxygen species rather than ATP. This is the mechanism by which MOTS-c functions as what the research literature calls an exercise mimetic — it activates many of the same adaptive pathways that sustained physical exercise activates, including increased mitochondrial density and improved metabolic flexibility.4

The folate cycle connection

Lee et al.’s founding 2015 paper also identified a more granular mechanism: MOTS-c inhibits the folate cycle and de novo purine biosynthesis in skeletal muscle under metabolic stress — redirecting metabolic resources toward energy production rather than biosynthesis. This metabolic rebalancing prevents the accumulation of intermediates that impair insulin signaling and contributes to the AMPK-dependent glucose clearance effect.1 It is a level of mechanistic specificity unusual in the peptide research literature and one reason the 2015 paper attracted significant scientific attention.

03 · What the Research Shows

The evidence, read honestly.

MOTS-c has accumulated a substantial research base since its 2015 discovery — published across multiple independent research groups in journals including Cell Metabolism, Diabetes, and Frontiers in Endocrinology. The evidence base is more independently diverse than most peptides in this catalog. The consistent caveat: no large-scale human RCT has been completed. Most data is from rodent models and cell culture.

04 · Why It Matters After 40

Menopause is not just a hormone story. It is a mitochondrial story — and MOTS-c research knows the difference.

Estrogen is mitochondrial-protective. This is not a widely discussed fact in mainstream menopause education, but it is established biology — estrogen supports mitochondrial biogenesis, reduces mitochondrial oxidative stress, and maintains the energy metabolism efficiency that mitochondria depend on. When estrogen levels decline during perimenopause and menopause, the mitochondrial environment changes: energy production becomes less efficient, oxidative damage accumulates faster, and the metabolic flexibility that allowed cells to shift cleanly between glucose and fat as fuel sources becomes impaired.

This mitochondrial shift is mechanistically upstream of many of the metabolic symptoms women experience in the menopausal transition — the weight redistribution that doesn’t respond to prior dietary patterns, the energy floor that seems lower than it used to be, the insulin sensitivity changes that arrive without clear dietary cause. These are not simply hormonal symptoms. They are metabolic symptoms with a mitochondrial origin.

MOTS-c is one of the only compounds in the research peptide space with a published study specifically examining its effects on menopausal metabolic dysfunction — not inferred, not extrapolated, but tested in an ovariectomized mouse model designed to replicate menopausal hormonal conditions. The AMPK-dependent reversal of those metabolic changes is documented. The human translation is the research question. The mechanistic rationale for investigating it is unusually direct.

For the full account of the mitochondrial biology of menopause and cellular longevity after 40, see You’re Not Tired Because You’re Aging. You’re Tired Because Your Cells Are Running Out of Power. That piece covers the system. This one covers the compound.

Cellular Standard — MOTS-c
Card 01 · Molecular Identity
Research Peptide
MOTS-c
Cellular STANDARD
Molecular Identity
10 mg Mitochondrial-Derived Peptide
CAS Number
1627580-64-6
Molecular Weight
2,174.6 g/mol
Molecular Formula
C₁₀₁H₁₅₂N₂₈O₂₂S₂
Peptide Class
Mitochondrial-derived · 16 aa
Mechanism
AMPK activation · Retrograde signaling
Storage
-20°C · 24 mo
Origin
Mitochondrial DNA · MT-RNR1
HPLC Verified
Mass Spec Confirmed
Endotoxin Free
USA Operated
For Research Use Only
Card 02 · Primary Structure
Research Peptide
MOTS-c
Cellular STANDARD
Primary Structure
10 mg Mitochondrial-Derived Peptide
M
1
R
2
W
3
Q
4
E
5
M
6
G
7
Y
8
I
9
F
10
Y
11
P
12
R
13
K
14
L
15
R
16
Residues 1–11 conserved across 14 species · Encoded by mtDNA MT-RNR1
Met · Arg · Trp · Gln · Glu · Met · Gly · Tyr · Ile · Phe · Tyr · Pro · Arg · Lys · Leu · Arg
Hydrophobic
Polar / charged
CAS #
1627580-64-6
Formula
C₁₀₁H₁₅₂N₂₈O₂₂S₂
M.W.
2,174.6 g/mol
Class
MDP · 16 aa
Origin
Endogenous
Storage
-20°C · 24 mo
For Research Use Only
Card 03 · Research Profile
Research Peptide
MOTS-c
Cellular STANDARD
Research Profile
10 mg AMPK · Retrograde Signaling
Metabolic
Stress
Trigger
→
Mito­chondria
→ MOTS-c
Retrograde signal
→
AMPK
Activation
Nucleus
→
Glucose
Uptake · FAO
Metabolic reset
Under metabolic stress, mitochondria release MOTS-c as a retrograde signal — it travels to the nucleus, activates AMPK, and resets nuclear gene expression toward efficient energy utilization, insulin sensitivity, and mitochondrial biogenesis.
Insulin sensitivity
GLUT4 translocation; glucose uptake independent of insulin signaling
Exercise mimetic
Endurance enhancement; metabolic adaptation without exercise stimulus
Menopausal metabolism
AMPK-dependent reversal of menopausal metabolic dysfunction in animal models
Neuroprotection
Amyloid-beta reduction; hippocampal memory improvement in aged models
Research models
In vitroRodentC. elegansNo human RCT
For Research Use Only

Continue reading
Woman laughing at outdoor café, full of energy — Cell Rituals cellular longevity after 40
Cellular Longevity

You’re Not Tired Because You’re Aging. You’re Tired Because Your Cells Are Running Out of Power.

June 24, 2026

A science-led guide to why mitochondrial function is the foundation of biological aging, what changes after 40 at the cellular level, and what the research is exploring about MOTS-c, NAD+, and SS-31.

Aging is not a clock. It is a mitochondrial story.

The fatigue that does not resolve with sleep. The metabolism that no longer responds to effort. The recovery that takes longer than it used to. The cognitive sharpness that comes and goes. The sense that your body is running at a different wattage than it used to.

These experiences are connected at a level most health conversations never reach. They share a common biological foundation: the progressive decline in mitochondrial function that occurs with age — and that accelerates around the hormonal transition of perimenopause and menopause.

This is not a pessimistic story. It is a mechanistic one. And mechanisms can be understood, studied, and addressed. This guide covers the biology of cellular aging with precision, what mitochondrial decline actually means for the female body after 40, and what the research is exploring at the molecular level — honestly, with citations, without extrapolation.

What mitochondria actually do — and what happens when they decline

Mitochondria are present in nearly every cell in the human body. Their primary function is the production of ATP — adenosine triphosphate — the energy currency that powers every cellular process: muscle contraction, neuronal firing, immune response, hormonal signaling, tissue repair, DNA maintenance. Without adequate ATP, these processes slow, falter, or fail.

The mechanism of ATP production — oxidative phosphorylation through the electron transport chain — is one of the most sophisticated biological processes in existence. It is also one of the most vulnerable to age-related damage. And its decline does not occur in isolation.

The electron transport chain and Complex I

The electron transport chain consists of five protein complexes embedded in the inner mitochondrial membrane. Electrons flow through these complexes, driving the production of a proton gradient that powers ATP synthase — the molecular turbine that generates ATP. Complex I, the first and most vulnerable of these complexes, shows approximately 40% reduced activity with aging, documented in the American Journal of Physiology.¹ When Complex I fails, electrons leak and react with oxygen prematurely, creating reactive oxygen species — the oxidative damage that compounds mitochondrial dysfunction over time.

The NAD+ decline

NAD+ (nicotinamide adenine dinucleotide) is an essential coenzyme for mitochondrial function — a molecular shuttle that carries electrons through the electron transport chain. Without adequate NAD+, the chain cannot operate. NAD+ also serves as the substrate for sirtuins — the family of proteins responsible for DNA repair, epigenetic regulation, and metabolic adaptation.

NAD+ levels decline with age, partly due to increased activity of CD38, an enzyme that degrades NAD+ and becomes more active as inflammation increases. By midlife, NAD+ levels may be roughly half of what they were at age 20. This decline is not cosmetic — it directly affects the capacity of every mitochondrion in the body to produce energy.²

The menopause acceleration

Estradiol has direct mitochondrial protective effects — enhancing Complex I and IV function, maintaining mitochondrial membrane potential, and reducing reactive oxygen species production. When estradiol declines during perimenopause and menopause, mitochondrial function declines with it. This is the biological mechanism behind the fatigue, metabolic shift, cognitive fog, and body composition changes that many women notice in this transition — a mitochondrial withdrawal, not simply a hormonal one.³

The hallmarks of aging — mitochondria at the center

A landmark 2013 review in Cell identified nine hallmarks of aging — the key biological processes that drive age-related decline. Mitochondrial dysfunction sits at the center of this framework, not as a symptom of other hallmarks but as a driver of them. Genomic instability, epigenetic alterations, cellular senescence, deregulated nutrient sensing — all are connected to and amplified by declining mitochondrial function.⁴

What the research is exploring: MOTS-c, NAD+, and SS-31

Three compounds have generated the most significant research interest for their potential to address mitochondrial decline at the cellular level. Each operates through a distinct mechanism — and together they address different aspects of mitochondrial biology.

MOTS-c — the mitochondrial messenger

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid peptide encoded not in nuclear DNA but in mitochondrial DNA itself. It was identified in 2015 by Lee et al. at the University of Southern California — a discovery that established that mitochondria have their own peptide-based signaling system, separate from nuclear gene regulation.

MOTS-c functions as a retrograde signaling molecule: when cells are under metabolic stress, mitochondria upregulate MOTS-c production, which travels to the nucleus and activates AMPK — the master metabolic regulator — driving a shift toward more efficient energy utilization, reduced inflammation, and enhanced insulin sensitivity.

WHAT WE KNOWThe 2015 Cell Metabolism paper by Lee et al. demonstrated that MOTS-c administration in high-fat diet mice prevented diet-induced obesity and insulin resistance, with treated mice eating the same diet as controls but maintaining metabolic health. MOTS-c activates AMPK, which upregulates PGC-1alpha — the master regulator of mitochondrial biogenesis — supporting the creation of new mitochondria alongside repair of existing ones. Anti-inflammatory effects have been documented, with research showing suppression of NF-kappa B activation and downstream inflammatory cytokines. MOTS-c has been shown to cross the blood-brain barrier in animal studies, with neuroprotective effects including reduced amyloid-beta accumulation and improved hippocampal-dependent memory in aged models.
WHAT WE DON’T KNOWLarge-scale human clinical trials are not yet published. The mouse model findings on obesity prevention, while compelling, have not been replicated at clinical scale in humans. Optimal dosing, cycling protocols, and long-term effects in humans — particularly perimenopausal and postmenopausal women — have not been established through rigorous trials. The neuroprotective findings are from animal models and require human replication. MOTS-c levels decline with age in humans, but whether exogenous supplementation produces equivalent biological effects to endogenous signaling is an open question.
WHAT THAT MEANSMOTS-c is among the most mechanistically interesting compounds in the mitochondrial research space — and one of the only compounds encoded in mitochondrial DNA itself, giving it a biological specificity that distinguishes it from externally derived molecules. The animal and in vitro research is compelling and consistent. The human clinical evidence is early. For the woman after 40 experiencing the metabolic and energy consequences of mitochondrial decline compounded by hormonal transition, the mechanism is precisely relevant — the data just needs to mature.

NAD+ — the cellular fuel line

NAD+ is not a peptide — it is a coenzyme present in every living cell. Its role in mitochondrial function is foundational: it serves as the electron carrier that makes oxidative phosphorylation possible, and as the substrate for sirtuins, the proteins that regulate DNA repair, epigenetic maintenance, and stress resistance. The decline of NAD+ with age is one of the most replicated findings in longevity biology.

WHAT WE KNOWNAD+ decline with age is well documented and mechanistically understood — driven partly by increased CD38 activity, which degrades NAD+ and becomes more active as inflammation increases. A 2018 study in PNAS by Hou et al. showed NAD+ precursor supplementation reduced tau pathology and improved cognitive function in a mouse model of Alzheimer’s disease combined with DNA repair deficiency. Sirtuin activation by NAD+ is one of the most studied pathways in longevity biology, with documented effects on mitochondrial biogenesis, DNA repair, and metabolic regulation. A 2012 Cell Metabolism study by Canto et al. showed NAD+ precursor supplementation increased mitochondrial oxidative metabolism and protected against high-fat diet-induced obesity in mice.
WHAT WE DON’T KNOWMost compelling NAD+ research uses precursors (NR or NMN) rather than direct NAD+ administration, raising questions about the most effective delivery mechanism. Translation from mouse models to human outcomes at clinical scale is not fully established. The optimal approach to restoring NAD+ levels in aging humans — dosing, form, timing, and combination with other interventions — is an active research area without consensus. Long-term safety data in humans is limited.
WHAT THAT MEANSNAD+ has one of the strongest research foundations of any compound in the longevity space — the mechanism is well characterized, the age-related decline is documented, and the sirtuin/DNA repair pathway is among the most studied in biogerontology. The human clinical translation is still maturing. For the woman after 40 experiencing the compounded effects of NAD+ decline alongside hormonal transition, this is a compound whose biology is worth understanding in depth.

SS-31 — the structural engineer

SS-31 (also known as Elamipretide) is a small synthetic peptide developed by Hazel Szeto at Cornell University. Its mechanism is architecturally specific: it carries a positive charge and integrates directly into the inner mitochondrial membrane — the site where the electron transport chain operates — where it stabilizes cardiolipin, the phospholipid critical for electron transport chain function, and scavenges reactive oxygen species at their source.

Where MOTS-c promotes new mitochondrial biogenesis and NAD+ restores the fuel supply, SS-31 addresses the structural integrity of the membrane itself — the physical substrate on which energy production depends.

WHAT WE KNOWSS-31 has demonstrated the ability to stabilize cardiolipin, restore mitochondrial membrane potential, and reduce reactive oxygen species production in animal studies across multiple tissue types. A 2017 JAHA study showed SS-31 administered after cardiac ischemia-reperfusion injury significantly reduced infarct size and improved mitochondrial function in surviving cardiac tissue. Human clinical trials exist — the PROGRESS-HF trial tested SS-31 in heart failure with preserved ejection fraction, showing improvements in exercise capacity and quality of life measures, representing one of the few peptide mitochondrial compounds with Phase II human clinical data. Cognitive benefits have been documented in aged animal models.
WHAT WE DON’T KNOWHuman clinical data for SS-31 exists primarily in cardiovascular contexts. Cognitive and metabolic applications in humans — particularly in women experiencing age-related mitochondrial decline — have not been studied in rigorous trials. Long-term safety across extended use periods is not established. Optimal administration routes and dosing for non-cardiovascular applications are not defined by published research.
WHAT THAT MEANSSS-31 has a more substantial human clinical data foundation than most peptides discussed in longevity contexts — it has reached Phase II trials. The mechanism is precisely characterized and the structural membrane target is well defined. The gap is the translation to the broader metabolic and cognitive applications most relevant to women after 40. The cardiovascular data is genuinely compelling and the mechanistic case for broader mitochondrial benefit is strong.

Why these three compounds address different layers of the same problem

Mitochondrial dysfunction is not a single failure. It involves faulty signaling — the mitochondria’s communication with the rest of the cell breaks down. It involves energy shortage — the fuel supply for the electron transport chain is depleted. And it involves structural decay — the physical membrane on which energy production depends degrades under oxidative damage.

MOTS-c addresses the signaling layer — activating the cellular programs that build new mitochondria and restore metabolic efficiency. NAD+ addresses the fuel layer — restoring the coenzyme that powers the electron transport chain and the sirtuins that maintain genomic integrity. SS-31 addresses the structural layer — protecting and restoring the mitochondrial membrane itself.

This is not a protocol claim. It is a mechanistic description of three distinct biological problems and the compounds being studied to address them. The research on each is at different stages of maturity. What connects them is that they all converge on the same fundamental question: can the trajectory of mitochondrial decline that drives so much of what we experience as aging be meaningfully altered at the cellular level?

The honest answer is: the animal research says yes, compellingly. The human clinical research is earlier and more limited. The mechanisms are real. The translation is still being established.

What this means for you

If you are after 40 and something has changed in your energy, your metabolism, your recovery, your cognitive sharpness — that change is not random. It has a cellular explanation. The mitochondrial decline of aging, compounded by the mitochondrial protective effects of estradiol withdrawal, produces a specific and predictable biological signature.

What the science supports clearly: mitochondrial function declines with age through documented mechanisms — Complex I degradation, NAD+ depletion via CD38, reactive oxygen species accumulation, and membrane structural decay. These are not theoretical. They are measured, published, replicated findings.

What the research is exploring: whether compounds that act at the specific layers of mitochondrial failure — signaling, fuel supply, structural integrity — can meaningfully alter the trajectory of cellular aging. The animal data is consistent and compelling. The human data is earlier and less complete. The biology is real. The clinical translation is still being written.

Understanding the mitochondrial layer of your own biology is where the most consequential health decisions start. Not because there is a simple answer, but because the question is the right one.

Verified Citations
All citations verified against published sources. Compound-specific claims follow the good/bad/unknown framework — no extrapolation beyond published study protocols.
1Navarro A, Boveris A. The mitochondrial energy transduction system and the aging process. Am J Physiol Cell Physiol. 2007;292(2):C670–686.
2Camacho-Pereira J, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 2016;23(6):1127–1139.
3Irwin RW, et al. Progesterone and estrogen regulate oxidative metabolism in brain mitochondria. Endocrinology. 2008;149(6):3167–3175.
4Lopez-Otin C, et al. The hallmarks of aging. Cell. 2013;153(6):1194–1217.
5Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454.
6Canto C, et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 2012;15(6):838–847.
7Hou Y, et al. NAD+ supplementation normalizes key Alzheimer’s features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proc Natl Acad Sci. 2018;115(8):E1876–E1885.
8Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029–2050.
9Daubert MA, et al. Novel mitochondria-targeting peptide in heart failure treatment. JACC Heart Fail. 2017;5(2):149–157.
10Kumagai H, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2022;13(1):7650.
11Wan Z, et al. MOTS-c extends lifespan via modulation of cellular metabolism and stress response. Aging Cell. 2021;20(2):e13323.
Continue reading

The Peptide Pulse

Science-led. Women-first.
Delivered to your inbox.

The research, the compounds, the questions worth asking.
No agenda. No selling. Just the science.

By subscribing you agree to our Privacy Policy.